← 返回

癌症免疫治疗:进展与瓶颈

英文原题:Cancer immunotherapies: advances and bottlenecks.

查看英文原题

Cancer immunotherapies: advances and bottlenecks.

PubMed 2023/08/24(内容时间) Front Immunol Q1 · IF 7(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

免疫治疗开创了癌症治疗的新时代,而癌症免疫治疗持续焕发新生。癌症免疫治疗的临床目标是激活宿主免疫系统,以提供针对恶性肿瘤的被动或主动免疫。肿瘤浸润白细胞(TILs)在肿瘤微环境(TME)中发挥免疫调节作用,这与肿瘤细胞的免疫逃逸密切相关,从而影响肿瘤进展。包括免疫检查点抑制剂(ICIs)、癌症疫苗、过继细胞转移(ACT)在内的多种癌症免疫疗法已显示出巨大疗效和前景。在这篇综述中,我们将总结肿瘤免疫治疗的最新研究进展,包括免疫治疗的分子机制、临床效果以及局限性。

展开英文摘要原文

Immunotherapy has ushered in a new era in cancer treatment, and cancer immunotherapy continues to be rejuvenated. The clinical goal of cancer immunotherapy is to prime host immune system to provide passive or active immunity against malignant tumors. Tumor infiltrating leukocytes (TILs) play an immunomodulatory role in tumor microenvironment (TME) which is closely related to immune escape of tumor cells, thus influence tumor progress.

Several cancer immunotherapies, include immune checkpoint inhibitors (ICIs), cancer vaccine, adoptive cell transfer (ACT), have shown great efficacy and promise. In this review, we will summarize the recent research advances in tumor immunotherapy, including the molecular mechanisms and clinical effects as well as limitations of immunotherapy.

论文信息

作者
Rui R、Zhou L、He S
单位
Department of Urology, Peking University First Hospital, Beijing, China.China
文献类型
综述 · 非美国政府资助研究
期刊
Frontiers in immunology2023
原文标识
PubMed 37691932 · DOI 10.3389/fimmu.2023.1212476